MEMORANDUM OF UNDERSTANDING ("MOU")

between

the World Health Organization,
20 avenue Appia, 1211Geneva, Switzerland
("WHO")

and

the International Network of Agencies for Health Technology Assessment
c/o SBU P.O. Box 5650
SE-114 86 Stockholm, Sweden
("INAHTA")

WHEREAS WHO, through its Department of Essential Health Technologies aims to promote to ensure improved access, quality and use of health technologies.

WHEREAS the aim of INAHTA, a non profit organization, is to provide a forum for the identification and pursuit of interests common to health technology assessment agencies;

WHEREAS WHO and INAHTA, hereinafter also referred to as "the Parties", believe that technical collaboration between the two organizations will contribute to the shared goals of promoting the wide availability of information for the assessment of safe, effective, and affordable health technologies to promote better health care.

WHEREAS the Parties furthermore believe that agreement in advance on certain aspects of individual collaborative projects (as the Parties may identify on a case-by-case basis) will facilitate the early implementation of such projects, in particular by facilitating the conclusion of the agreements to which such projects would be subject;

NOW, therefore, the Parties hereby agree as follows:

1. **Areas of collaboration**

INAHTA will collaborate with WHO to support health technology assessment initiatives in developing countries.

INAHTA will collaborate with WHO in the implementation of the WHA60.29 attached to this MOU and entitled Health Technologies Resolution, including, without limitation, information for the health technologies clearinghouse,

Subject to WHO rules and regulations, INAHTA Board members may be invited to participate in Health Technologies meetings organized by WHO.

2. **Collaborative activities**

Any collaborative activity as outlined in article 1 above shall be subject to the availability of sufficient financial and human resources for that purpose, as well as each Party’s programme of work, priority activities, internal rules, regulations, policies, administrative procedures and practices. Each collaborative activity shall thus be agreed on a case-by-case basis, subject to a separate exchange of letters or agreement.
3. **Confidentiality**

Except as explicitly provided in this MOU, each party shall take all reasonable measures to keep confidential any information specifically marked “confidential” about the other party that comes to its knowledge during the implementation of this Agreement. However, there shall be no obligation of confidentiality where: (i) the information is publicly available, or becomes publicly available, otherwise than by action or omission of the receiving party, or (ii) the information was already known to the receiving party (as evidenced by its written records) prior to its receipt; or (iii) the information was received from a third party not in breach of an obligation of confidentiality owed to the other party. In the event that a Party is in possession of special confidential information, which is proprietary to it or to third parties collaborating with it, that Party may require the conclusion of a separate confidential disclosure agreement for the sharing of such information with the other Party.

4. **Publications**

4.1 Subject to each Party’s proprietary rights and/or the proprietary rights of others, and without prejudice to obligations of confidentiality, the results of any collaborative activity under this MOU may be published by either Party. The Parties are encouraged to publish the results of their joint work in a collaborative fashion. Guidelines for authorship of major, international, peer-reviewed journals will be used to establish authorship of collaborative publications. In regard to separate publications, it is agreed that in order to avoid prejudicing proprietary rights and the confidentiality of information, the publishing Party shall transmit to the other party for its review the material intended to be published at least 60 (sixty) days before a proposed publication is submitted to any editor, publisher, referee or meeting organizer. In the absence of any objection by the other Party within that 60 day period, concerning prejudice to proprietary rights or confidentiality of information, the publication may proceed. Any publication as referred to above shall duly acknowledged both Parties. In addition to review of the content of publications as referred to above, each Party shall have the right to review the acknowledgement and request reasonable changes to the use of its name, or request that its name be deleted altogether.

4.2 Copyright in any jointly prepared publications resulting from or relating to any of the collaborative activities under this MOU shall be vested in WHO and INAHITA jointly, who shall each independently and severally be entitled to exploit such copyright in any manner and for any purpose as they may each in their sole discretion deem appropriate, except that no use shall be made of such publications for or in conjunction with commercial and/or promotional purposes.

4.3 Copyright in any publications resulting from or relating to any of the collaborative activities under this MOU, and prepared by one of the Parties hereto on its own, shall be vested in that Party, provided however, that any such publication shall be submitted to the other Party for review and comments in accordance with paragraph 4.1 above.

5. **Liability**

5.1 Each Party shall be solely responsible for the manner in which it carries out its part of the collaborative activities under this MOU. Thus, a Party shall not be responsible for any loss, accident, damage or injury suffered or caused by the other Party, or that other Party’s staff or subcontractors, in connection with, or as a result of, the collaboration under this MOU.

5.2 The Parties shall make appropriate arrangements to cover liability risks for any collaborative activities involving product research and development.
6. **Use of the Parties’ names**

Except as explicitly provided in this MOU, neither Party shall, in any statement or material of a promotional nature, refer to the relationship of the other Party to the collaboration pursuant to this MOU, or otherwise use the other Party’s name, acronym and/or emblem, without the prior written consent of the other Party.

7. **Relationship of the Parties**

For the purposes of this MOU, each Party is an independent contractor and not the joint venturer, agent or employee of the other Party. Neither Party shall have authority to make any statements, representations, or commitments of any kind, or to take any action which shall be binding on the other Party, except as may be explicitly provided for in this MOU or authorized in writing by the other Party.

8. **Termination**

This MOU may be terminated by either Party, subject to six months advance written notice to the other Party. Notwithstanding the foregoing, it is agreed that any termination of this MOU shall be without prejudice to: (i) the orderly completion of any ongoing collaborative activity; and (ii) any other rights and obligations of the Parties accrued prior to the date of termination of this MOU.

9. **Amendments**

This MOU may only be amended in writing by mutual consent of the Parties.

10. **Settlement of disputes**

Any dispute relating to the interpretation or execution of this MOU, or of any subsequent exchange of letters or agreement with respect to individual collaborative activities shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the Parties, or in the absence of agreement, in accordance with the rules of arbitration of the International Chambre of Commerce. The Parties shall accept the arbitral award as final.

Agreed and accepted:

For The World Health Organization     For The International Network of Agencies for Health Technology Assessment

Name: Steffen Groth                      Name: Guy Maddern
Title: Director of Essential Health Technologies Title: Chairman
Date: 24 June, 2009                     Date: 24 June, 2009.
Health technologies\(^1\)

The Sixtieth World Health Assembly,

Having considered the report on health technologies;\(^2\)

Recognizing that health technologies equip health-care providers with tools that are indispensable for effective and efficient prevention, diagnosis, treatment and rehabilitation and attainment of internationally agreed health-related development goals, including those contained in the Millennium Declaration;

Understanding that health technologies in particular medical devices represent an economic as well as a technical challenge to the health systems of many Member States, and concerned about the waste of resources resulting from inappropriate investments in health technologies in particular medical devices that do not meet high-priority needs, are incompatible with existing infrastructures, are irrationally or incorrectly used, or do not function efficiently;

Acknowledging the need for Member States and donors to contain burgeoning costs by establishing priorities in the selection and acquisition of health technologies in particular medical devices on the basis of their impact on the burden of disease, and to ensure the effective use of resources through proper planning, assessment, acquisition and management;

Noting the need to expand expertise in the field of health technologies in particular medical devices;

1. URGES Member States:

   (1) to collect, verify, update and exchange information on health technologies in particular medical devices as an aid to their prioritization of needs and allocation of resources;

   (2) to formulate as appropriate national strategies and plans for the establishment of systems for the assessment, planning, procurement and management of health technologies in particular medical devices, in collaboration with personnel involved in health-technology assessment and biomedical engineering;

---

\(^1\) The term “health technologies refers to the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives”.

\(^2\) Document A60/26.
(3) to draw up national or regional guidelines for good manufacturing and regulatory practices, to establish surveillance systems and other measures to ensure the quality, safety and efficacy of medical devices and where appropriate participate in international harmonization;

(4) to establish where necessary regional and national institutions of health technology, and to collaborate and build partnerships with health-care providers, industry, patients' associations and professional, scientific and technical organizations;

(5) to collect information that interrelates medical devices, which deal with priority public-health conditions at different levels of care and in various settings and environments, with the required infrastructure, procedures and reference tools;

2. REQUESTS the Director-General:

(1) to work with interested Member States and WHO collaborating centres on the development, in a transparent and evidence-based way, of guidelines and tools, including norms, standards and a standardized glossary of definitions relating to health technologies in particular medical devices;

(2) to provide support to Member States where necessary in establishing mechanisms to assess national needs for health technologies in particular medical devices and to assure their availability and use;

(3) to develop methodological tools to support Member States in analysing their health technologies in particular medical devices needs and health-system prerequisites;

(4) to provide technical guidance and support to Member States where necessary in implementing policies on health technologies, in particular medical devices especially for priority diseases, according to different levels of care in developing countries;

(5) to work jointly with other organizations of the United Nations system, international organizations, academic institutions and professional bodies in order to provide support to Member States in the prioritization, selection and use of health technologies in particular medical devices;

(6) to establish and update regularly an evidence and web-based health technologies database to serve as a clearing house which will provide guidance on appropriate medical devices according to levels of care, setting, environment, and intended health intervention, tailored to the specific needs of country or region;

(7) to provide support to Member States with vulnerable health-care systems so as to identify and put in place appropriate health technologies in particular medical devices that facilitate access to quality services in primary health care;

(8) to report on implementation of this resolution to the Executive Board and the Sixty-second World Health Assembly through the Executive Board.

Eleventh plenary meeting, 23 May 2007
A60/VR/11